ABAlain Beretz

Alain Beretz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alain Beretz has a total of 169 co-authors. Here are the top co-authors by number of shared publications:

  • J P Cazenave

    13 shared publications
  • Jean-Pierre Cazenave

    11 shared publications
  • C Klein-Soyer

    INSERM U. 311, Biologie et Pharmacologie des Interactions du Sang avec les Vaisseaux et les Biomatériaux, Strasbourg, France

    6 shared publications
  • François Lanza

    Institut National de la Santé et de la Recherche Médicale, Etablissement Français du Sang Grand Est, Unité Mixte de Recherche-S 1255, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg, France

    6 shared publications
  • Robert Anton

    † Laboratoire de Pharmacognosie, Université Louis Pasteur de Strasbourg, CNRS GDR 1206 Faculté de Pharmacie, BP 24, 67401 Illkirch-Cedex, France

    5 shared publications
  • J M Freyssinet

    INSERM U.311, Centre Régional de Transfusion Sanguine, 10 rue Spielmann, 67085 Strasbourg Cédex, France

    4 shared publications

Latest Publications

  • Open Access

    Mutations et défis de la gouvernance des universités

    by Alain Beretz, Romuald Normand


  • Open Access

    Allocution d’ouverture

    by Alain Beretz

    Je suis heureux d’accueillir le congrès de la Société francophone de philosophie de la religion à l’université de Strasbourg. Comme président de cette université, je me réjouis de constater que cette société compte parmi ses membres des membres enseignants-chercheurs de notre université, dont l’actuel président, Philippe Capelle-Dumont, qui est aussi un des fondateurs de cette société, ou son secrétaire, Yannick Courtel, directeur de notre école doctorale de théologi

  • Open Access

    Intake of grape‐derived polyphenols reduces C26 tumor growth by inhibiting angiogenesis and inducing apoptosis

    by Allison Walter, Nelly Etienne‐Selloum, David Brasse, Hadeel Khallouf, Christian Bronner, Marie‐Christine Rio, Alain Beretz, Valérie B. Schini‐Kerth

    This study evaluated the in vivo antitumor activity of grape‐derived polyphenols. BALB/c mice were subcutaneously implanted with C26 colon carcinoma cells, and 2 d later they received either solvent or red wine polyphenols (RWPs) (100 mg/kg/d, human equivalent dose ≈500 mg/d) in the drinking water for 25 d. Wistar rats received either solvent or RWPs (100 mg/kg/d, human equivalent dose ≈1000 mg/d) in the drinking water 1 wk before injection of azoxymethane and were studied 10 wk later. In mice, RWPs inhibited tumor growth by 31%, reduced tumor vascularization and the number of lung metastases, decreased proliferation as indicated by down‐regulation of Ki67, cyclin D1, and UHRF1, and increased apoptosis as indicated by TUNEL staining and active caspase‐3 levels in tumor cells. RWPs reduced expression of VEGF, matrix metalloproteinase (MMP)‐2, MMP‐9, and cyclooxygenase‐2 and increased expression of tumor suppressor genes p16 INK4A , p53, and p73 in tumor cells. In rats, RWPs reduced by 49% the number of azoxymethane‐induced aberrant crypt foci (preneoplastic lesions) in colon. Thus, RWPs effectively reduced the development of colon carcinoma tumors in vivo by blunting tumor vascularization and by inhibiting proliferation and promoting apoptosis of tumor cells subsequent to an up‐regulation of tumor suppressor genes.—Walter, A., Etienne‐Selloum, N., Brasse, D., Khallouf, H., Bronner, C., Rio, M.‐C., Beretz, A., Schini‐Kerth, V. B. Intake of grape‐derived polyphenols reduces C26 tumor growth by inhibiting angiogenesis and inducing apoptosis. FASEB J . 24, 3360–3369 (2010). www.fasebj.org


  • Red Wine Polyphenols Prevent Acceleration of Neovascularization by Angiotensin II in the Ischemic Rat Hindlimb

    by Allison Walter, Nelly Etienne-Selloum, David Brasse, René Schleiffer, Virgile Bekaert, Paul M. Vanhoutte, Alain Beretz, Valérie B. Schini-Kerth

    Studies in both animals and humans indicate that angiogenesis is implicated in the development of atherosclerotic lesions. Thus, inhibition of angiogenesis may provide a novel therapeutic approach for the treatment of atherosclerosis. Because epidemiological studies have indicated an inverse relation between red wine intake and coronary disease, we determined the antiangiogenic potential of red wine polyphenols (RWPs) in the ischemic hindlimb model. Neovascularization was accelerated by the chronic infusion of angiotensin II (Ang II; 0.1 mg/kg/day). RWPs (25 mg/kg/day) or vehicle were administrated in the drinking water 7 days before the ligation. After 21 days, Ang II potentiated the ischemia-induced neovascularization in the hindlimb, as assessed by microangiography and measurement of microvessel density. This effect was associated with an increased formation of reactive oxygen species (ROS) and increased expression of hypoxia-inducible factor (HIF)-2α, endothelial nitric-oxide synthase (eNOS), and vascular endothelial growth factor (VEGF). RWPs intake significantly prevented the angiogenic process, the formation of ROS and nitrated proteins, and the expression HIF-2α, eNOS, and VEGF induced by Ang II. Similar preventive effects were observed with the antioxidant and NADPH oxidase inhibitor apocynin. These findings indicate that RWPs have potent antiangiogenic properties in vivo by preventing the expression of proangiogenic factors, including VEGF and eNOS most likely by inhibiting oxidative stress. Thus, the antiangiogenic properties of red wine polyphenols might contribute to their protective effect against coronary disease.


  • Angiotensin II Induces the Vascular Expression of VEGF and MMP-2 in vivo: Preventive Effect of Red Wine Polyphenols

    by Allison Walter, Nelly Etienne-Selloum, Mamadou Sarr, Modou Oumy Kane, Alain Beretz, Valérie B. Schini-Kerth

    Objective: Previous investigations have indicated that angiotensin II (Ang II)-induced hypertension and endothelial dysfunction are prevented by intake of red wine polyphenols (RWPs). Ang II has also been shown to increase the expression of VEGF and MMP-2, two major pro-inflammatory factors, in vascular diseases. Therefore, the aim of the present study was to determine whether intake of RWPs is able to prevent these effects in rats and, if so, to characterize the underlying mechanism. Methods: VEGF and endothelial NO synthase (eNOS) expression was assessed by immunofluorescence and Western blotting, MMP-2 activity by zymography, and reactive oxygen species (ROS) formation by dihydroethidine. Results: Ang II increased VEGF expression and MMP-2 activity in the aortic wall. Ang II-induced MMP-2 activation is inhibited by NG-nitro-L-arginine and MnTMPyP. Ang II increased the expression of eNOS, the formation of ROS and the nitration of proteins. The stimulatory effects of Ang II on these factors are prevented by RWPs intake. Conclusions: Infusion of Ang II induced vascular expression of VEGF and peroxynitrite-dependent activation of MMP-2, with both effects being prevented by RWPs intake. Thus, prevention of VEGF and MMP-2 expression might be involved in the protective effect of red wine on coronary heart diseases.


    • 1 May 2007
      • Vol. 94  (5) , 483-8

    [Complementary and alternative medicines taken by cancer patients].

    by L Simon, D Prebay, Alain Beretz, J-L Bagot, A Lobstein, I Rubinstein, S Schraub

    244 cancer patients from 2 public hospitals (one adult, one pediatric) and one private clinic receiving chemotherapy were asked about complementary and alternative medicine (CAM). Nearly 28% used one or several CAM, especially homeopathy (60%), special diets or dietary supplements (44%), mistletoe (40%) and less frequently acupuncture or other treatments. These CAM are started 4 to 5 months after the onset of chemotherapy. The reasons for using CAM are enhance host defenses, better tolerance of treatment, but also for nearly 27% to treat cancer. All patients were treated by anticancer classical treatments and none thought to stop them. CAM are prescribed especially by homeopathic doctors. 30% of patients using CAM did not inform their oncologist of their CAM treatment. The same conclusions were drawn for the only 10 pediatric patients. The majority of all patients did not take any CAM before their cancer. In a multivariate analysis, female, young age (30-50 y) are correlated to CAM. All patients taking CAM are satisfied by the CAM treatment with good subjective results on their general status, fatigue and nausea-vomiting. These results are similar to other studies done in Europe.


  • Red Wine Polyphenolic Compounds Inhibit Vascular Endothelial Growth Factor Expression in Vascular Smooth Muscle Cells by Preventing the Activation of the p38 Mitogen-Activated Protein Kinase Pathway

    by Min-Ho Oak, Marta Chataigneau, ThérÈsE Keravis, Thierry Chataigneau, Alain Beretz, Ramaroson Andriantsitohaina, Jean-Claude Stoclet, Soon-Jae Chang, ValérIe B. Schini-Kerth

    Objective— Moderate consumption of red wine has a beneficial effect on the cardiovascular system. This study examines whether red wine polyphenolic compounds (RWPCs) affect vascular endothelial growth factor (VEGF) expression, a major angiogenic and proatherosclerotic factor in vascular smooth muscle cells (VSMCs). Methods and Results— VEGF mRNA expression was assessed by Northern blot analysis and the release of VEGF by immunoassay in cultured VSMCs. Short-term and long-term exposure of VSMCs to RWPCs inhibited VEGF mRNA expression and release of VEGF in response to platelet-derived growth factor AB (PDGF AB ), transforming growth factor-β 1 , or thrombin. The PDGF AB -induced expression of VEGF was markedly reduced by SB203580 (inhibitor of p38 mitogen-activated protein kinase [MAPK]), antioxidants, and diphenylene iodonium (inhibitor of flavin-dependent enzymes), slightly reduced by PD98059 (inhibitor of MEK), and not significantly affected by wortmannin (inhibitor of PI-3-kinase) and L-JNKI (inhibitor of JNK). Short-term and long-term treatment of VSMCs with RWPCs markedly reduced PDGF AB -induced production of reactive oxygen species and phosphorylation of p38 MAPK. Conclusions— These data indicate that RWPCs strongly inhibit growth factor–induced VEGF expression in VSMCs by preventing the redox-sensitive activation of the p38 MAPK pathway. The potential antiangiogenic and antiatherosclerotic properties of RWPCs are likely to contribute to cardiovascular protection by preventing the development of atherosclerotic lesions.


  • FAK-mediated Inhibition of Vascular Smooth Muscle Cell Migration by the Tetraspanin CD9

    by Arnaud Scherberich, Grégory Giannone, Elisabeth Perennou, Kenneth Takeda, Claude Boucheix, Eric Rubinstein, François Lanza, Alain Beretz

    Migration of vascular smooth muscle cells (SMC) towards the intima is a key event in vascular proliferative diseases. We investigated a potential role for the tetraspanin CD9 in this process in a wound migration assay. Aortic SMC from CD9 knock-out mice had higher migration rates and the presumably stimulatory anti-CD9 antibody ALMA-1 inhibited migration of human SMC. The signaling pathways responsible for this inhibitory effect were investigated. In migrating CD9−/− SMC, stress fiber formation was decreased and focal adhesions were smaller and more diffusely distributed, consistent with an inhibition of integrin clustering. In migrating mouse SMC expressing CD9, focal adhesion kinase (FAK) tyrosine phosphorylation was doubled. No differences in intracellular calcium signaling were observed between CD9+/+ and CD9−/− SMC during migration. We suggest that CD9 inhibits SMC migration by a stimulation of both stress fiber formation and integrin clustering, leading to a stimulation of FAK phosphorylation. * Present address: Friedrich Miescher Institute for Biomedical Research, Maulbeerstraße 66, CH-4058 Basel, Switzerland